SK Life Science

SK Life Science is a subsidiary of SK Biopharmaceuticals, Co., Ltd., dedicated to developing and marketing treatments for central nervous system (CNS) disorders. The company has eight products in development targeting CNS diseases, including epilepsy, sleep disorders, and attention deficit hyperactivity disorder (ADHD). Its lead product is cenobamate, an investigational compound currently being studied as a potential treatment option for patients with epilepsy.